Combination vaccine

Patent metadata

Field	Value
Publication number	US-2025360196-A1
Application number	US-202519204355-A
Country	US
Kind code	A1
Filing date	May 9, 2025
Priority date	Aug 21, 2013
Publication date	Nov 27, 2025
Grant date	—

Abstract

The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

First claim

1 - 35 . (canceled)

36 . A pharmaceutical composition comprising:
i) at least a first mRNA comprising a protein coding sequence encoding at least the extracellular domain of a human respiratory syncytial virus (RSV) Fusion protein (F); and ii) at least a second mRNA comprising a protein coding sequence encoding at least the extracellular domain of a human influenza virus Hemagglutinin (HA) protein.

37 . The pharmaceutical composition of claim 36 , wherein the first and second mRNAs comprise 5′ Cap structures.

38 . The pharmaceutical composition of claim 37 , wherein the first and second mRNAs comprise poly-A sequence of about 50 to about 250 adenosine nucleotides.

39 . The pharmaceutical composition of claim 38 , wherein the first and second mRNAs comprise 5′ and/or 3′ UTR sequences.

40 . The pharmaceutical composition of claim 39 , wherein the protein coding sequence of the first and second mRNAs is modified to increase the G/C content.

41 . The pharmaceutical composition of claim 39 , wherein the first and second mRNAs are complexed with a cationic or polycationic compound.

42 . The pharmaceutical composition of claim 41 , wherein the first and second mRNAs are complexed with a cationic or polycationic protein.

43 . The pharmaceutical composition of claim 41 , wherein the first and second mRNAs are complexed with a cationic lipid.

44 . The pharmaceutical composition of claim 39 , wherein the HA protein is a full-length HA protein.

45 . The pharmaceutical composition of claim 39 , wherein the F protein is a full-length HA protein.

46 . The pharmaceutical composition of claim 39 , wherein the HA protein is an Influenza A HA protein.

47 . The pharmaceutical composition of claim 46 , wherein the Influenza A HA protein is from H1N1, H1N2, H3N1, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H9N1, H9N2 or H10N7 Influenza.

48 . The pharmaceutical composition of claim 47 , wherein the Influenza A HA protein is H1 HA protein.

49 . The pharmaceutical composition of claim 39 , wherein the HA protein is an Influenza B HA protein.

50 . The pharmaceutical composition of claim 39 , wherein the composition comprises a further mRNA encoding a further antigen.

51 . The pharmaceutical composition of claim 50 , wherein the further antigen is an Influenza HA protein.

52 . The pharmaceutical composition of claim 40 , wherein the first and second mRNAs are complexed with a cationic lipid.

53 . The pharmaceutical composition of claim 52 , wherein the HA protein is an Influenza A HA protein.

54 . The pharmaceutical composition of claim 53 , wherein the HA protein is a full-length HA protein.

55 . A method of stimulating an immune response in a subject comprising administering an effective amount of the pharmaceutical composition of claim 36 to the subject.

Assignees

• CureVac SE

Inventors

• Kallen Karl-Josef
• Kramps Thomas
• Schnee Margit
• Voss Daniel

Classifications

• C12N2760/18534

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K14/005

  from viruses · CPC title

• A61K2039/575

  humoral response · CPC title